

Development and Validation of a Penicillin Allergy Clinical Decision Rule

Jason A. Trubiano, MBBS, PhD; Sara Vogrin, MBBS, MBIostat; Kyra Y. L. Chua, MBBS, PhD; Jack Bourke, MBBS; James Yun, MBBS, PhD; Abby Douglas, MBBS; Cosby A. Stone, MD; Roger Yu, MD; Lauren Groenendijk, MD; Natasha E. Holmes, MBBS, PhD; Elizabeth J. Phillips, MD

[+ Supplemental content](#)

IMPORTANCE Penicillin allergy is a significant public health issue for patients, antimicrobial stewardship programs, and health services. Validated clinical decision rules are urgently needed to identify low-risk penicillin allergies that potentially do not require penicillin skin testing by a specialist.

OBJECTIVE To develop and validate a penicillin allergy clinical decision rule that enables point-of-care risk assessment of patient-reported penicillin allergies.

DESIGN, SETTING, AND PARTICIPANTS In this diagnostic study, a multicenter prospective antibiotic allergy–tested cohort of 622 patients from 2 tertiary care sites in Melbourne, Australia (Austin Health and Peter MacCallum Cancer Centre) was used for derivation and internal validation of a penicillin allergy decision rule. Backward stepwise logistic regression was used to derive the model, including clinical variables predictive of a positive penicillin allergy test result. Internal validation of the final model used bootstrapped samples and the model scoring derived from the coefficients. External validation was performed in retrospective penicillin allergy–tested cohorts consisting of 945 patients from Sydney and Perth, Australia, and Nashville, Tennessee. Patients who reported a penicillin allergy underwent penicillin allergy testing using skin prick, intradermal, or patch testing and/or oral challenge (direct or after skin testing). Data were collected from June 26, 2008, to June 3, 2019, and analyzed from January 9 to 12, 2019.

MAIN OUTCOMES AND MEASURES The primary outcome for the model was any positive result of penicillin allergy testing performed during outpatient or inpatient assessment.

RESULTS From an internal derivation and validation cohort of 622 patients (367 female [59.0%]; median age, 60 [interquartile range {IQR}, 48–71] years) and an external validation cohort of 945 patients (662 female [70.1%]; median age, 55 [IQR, 38–68] years), the 4 features associated with a positive penicillin allergy test result on multivariable analysis were summarized in the mnemonic PEN-FAST: *penicillin allergy, five or fewer years ago, anaphylaxis/angioedema, severe cutaneous adverse reaction (SCAR), and treatment required for allergy episode*. The major criteria included an allergy event occurring 5 or fewer years ago (2 points) and anaphylaxis/angioedema or SCAR (2 points); the minor criterion (1 point), treatment required for an allergy episode. Internal validation showed minimal mean optimism of 0.003 with internally validated area under the curve of 0.805. A cutoff of less than 3 points for PEN-FAST was chosen to classify a low risk of penicillin allergy, for which only 17 of 460 patients (3.7%) had positive results of allergy testing, with a negative predictive value of 96.3% (95% CI, 94.1%–97.8%). External validation resulted in similar findings.

CONCLUSIONS AND RELEVANCE In this study, PEN-FAST was found to be a simple rule that accurately identified low-risk penicillin allergies that do not require formal allergy testing. The results suggest that a PEN-FAST score of less than 3, associated with a high negative predictive value, could be used by clinicians and antimicrobial stewardship programs to identify low-risk penicillin allergies at the point of care.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Jason A. Trubiano, MBBS, PhD, Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, 145 Studley Road, Heidelberg, Victoria, Australia 3084 (jason.trubiano@austin.org.au).

JAMA Intern Med. 2020;180(5):745-752. doi:10.1001/jamainternmed.2020.0403
Published online March 16, 2020.

Patient-reported penicillin allergies are frequently encountered in patients and significantly affect the judicious and appropriate use of antimicrobials.^{1,2} Penicillin allergies are also associated with antimicrobial resistance and poor patient outcomes.³⁻⁵ The success of antibiotic allergy testing (AAT) programs incorporated into antimicrobial stewardship (AMS) has been increasingly reported,^{2,6,7} frequently resulting in posttesting use of narrow-spectrum β -lactams.^{6,8,9} Formal AAT requires specialist interpretation, is labor intensive, and is potentially unwarranted, considering that less than 10% of penicillin allergies may be confirmed by formal testing results.² A validated point-of-care clinical decision rule is needed that can be used by allergists and nonallergists to address the high burden of penicillin allergies, risk stratify across a range of phenotypes, and subsequently direct the appropriate delabeling and prescribing strategies. This need is particularly relevant when we consider the apparent deficit of drug allergy specialists available internationally.¹⁰

An AMS-led AAT program was assessed in a prospective, multicenter observational study that examined the testing outcomes of a large population of patients with penicillin allergy who underwent AAT via predefined criteria.⁶ We used these data and an extended prospective Australian cohort to derive and internally validate a penicillin allergy clinical decision rule (PEN-FAST) and subsequently performed external validation in local and international data sets.

Methods

The derivation and validation of PEN-FAST was obtained from a prospective penicillin allergy-tested cohort across 2 sites in Melbourne, Australia; external validation, from 3 retrospective cohorts from Sydney and Perth, Australia, and Nashville, Tennessee. Adults 16 years or older were included from all sites. A summary of the derivation and validation cohorts is shown in **Table 1**. All data were obtained after approval of the ethics committee or institutional review board at each institution. Data collected retrospectively did not require informed consent. This study followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) reporting guideline.¹¹

Derivation and Internal Validation Cohort

A prospective cohort of patients undergoing AAT-AMS and recruited from May 1, 2015, to June 3, 2019, were included. In brief, AAT-AMS was simultaneously introduced at Austin Health and the Peter MacCallum Cancer Centre in Melbourne; the results of the first 118 patients have been previously published.⁶ Baseline demographic information, age-adjusted Charlson comorbidity index,¹² antibiotic allergy history, immunosuppression history, and allergy testing results were collected via a standardized case report form from a previous prospective study.⁶ The case report form and approach to phenotypic assessment are included in eMethods 1 and 2 in the **Supplement**.

Key Points

Question Can a clinical decision rule risk stratify penicillin allergies and identify low-risk phenotypes amenable to point-of-care delabeling?

Findings In this diagnostic study of 622 patients, a penicillin allergy decision rule (PEN-FAST) was derived from a prospective cohort of penicillin allergy-tested patients in 2 primary Australian sites and was subjected to internal and external validation in 3 local and international cohorts. PEN-FAST was found to be a practical tool with a high negative predictive value of 96.3% that uses penicillin allergy history to identify low-risk allergies.

Meaning PEN-FAST may aid the risk stratification of patients with penicillin allergy to facilitate implementation of delabeling strategies and safe β -lactam prescribing.

Patients who reported any penicillin allergy and underwent skin prick testing (SPT), intradermal testing (IDT), patch testing, and/or oral challenge (directly or after skin testing) were extracted from a prospective database. Patients with a negative SPT or IDT result who did not undergo subsequent oral penicillin challenge were excluded. Antibiotic allergy testing was performed for outpatients and inpatients as previously described for immediate and delayed hypersensitivities (eMethods 2 in the **Supplement**).^{6,13}

External Validation Cohorts

Two Australian retrospective outpatient penicillin allergy-tested cohorts from Royal North Shore Hospital, Sydney, from July 1, 2015, to December 31, 2017, and Royal Perth Hospital and Sir Charles Gairdner Hospital, Perth, from June 26, 2008, to June 20, 2013, and an additional cohort from Vanderbilt Asthma, Sinus and Allergy Program, Vanderbilt University Medical Center, Nashville, Tennessee, from January 1, 2014, to December 31, 2018, were used for external validation of the clinical decision rule. Available baseline demographic data and clinical information required to satisfy PEN-FAST criteria were extracted; if data were unavailable, they were listed as unknown. The summary of these cohorts is provided in Table 1. All cohorts included patients reporting a penicillin allergy who underwent testing using standard AAT protocols (eMethods 2 in the **Supplement**).^{6,8} Patients included had a positive SPT or IDT finding to any penicillin, a negative SPT or IDT finding followed by a penicillin oral challenge, or direct oral challenge with penicillin.

Definitions

A penicillin allergy was considered to include at least 1 of penicillin unspecified, penicillin VK, penicillin G, amoxicillin, ampicillin, dicloxacillin sodium, flucloxacillin, nafcillin sodium, or combined amoxicillin and clavulanate potassium. A patient-reported penicillin allergy was defined as a non-immune-mediated adverse drug reaction, immune-mediated reaction, or unknown, according to accepted criteria.^{14,15} An immunocompromised host was defined as a solid organ or hematological stem-cell transplant recipient, asplenic, having an autoimmune or connective tissue disorder, having cancer, or recipient of prednisone of more than 10 mg/d for more than 1 month.

Table 1. Patient and Testing Characteristics of the Penicillin Allergy-Tested Derivation and Validation Cohorts

Characteristic	Cohort			
	Melbourne, Australia ⁶	Sydney, Australia	Perth, Australia ⁸	Nashville, Tennessee
Cohort type	Prospective	Retrospective	Retrospective	Retrospective
No. of patients	622	80	334	531
Dates	May 1, 2015, to June 3, 2019	July 1, 2015, to December 31, 2017	June 26, 2008, to June 20, 2013	January 1, 2014, to December 31, 2018
Hospitals	Austin Health and Peter MacCallum Cancer Centre	Royal North Shore Hospital	Sir Charles Gardiner Hospital and Royal Perth Hospital	Vanderbilt University Medical Center
Inclusion criteria	Adults aged ≥ 18 y with ≥ 1 penicillin allergy	Adolescents and adults aged ≥ 16 y with ≥ 1 penicillin allergy	Adolescents and adults aged ≥ 16 y with ≥ 1 penicillin allergy	Adults aged ≥ 18 y with ≥ 1 penicillin allergy
Excluded phenotypes	AIN, DILI, serum sickness, drug fever (isolated)	AIN, DILI, serum sickness, drug fever (isolated)	SCAR, AIN, DILI, serum sickness, drug fever (isolated)	AIN, DILI, serum sickness, drug fever (isolated)
Testing sites	Inpatient/outpatient	Outpatient	Outpatient	Outpatient
Testing characteristics	SPT, IDT, PT, oral challenge (direct and after testing)	SPT, IDT, oral challenge (direct and after testing)	SPT, IDT, oral challenge (after testing)	SPT, IDT, PT, oral challenge (after testing)

Abbreviations: AIN, acute interstitial nephritis; DILI, drug-induced liver injury; IDT, intradermal testing; PT, patch testing; SPT, skin prick testing; SCAR, severe cutaneous adverse reaction.

In all cohorts (internal derivation and validation and external validation), a standard definition for AAT positivity was used (eMethods 2 in the Supplement). In all cohorts, penicillin VK or amoxicillin were used as the oral agent for post-skin testing challenges. A positive penicillin allergy test result was considered any 1 of a positive immediate SPT result, positive IDT result (immediate or delayed), positive patch test result, or positive oral challenge (single-dose or prolonged resulting in an immune-mediated reaction) to a penicillin reagent. No oral challenges were conducted to the specific drug with positive findings on skin testing (SPT or IDT); however, if drugs in the same class had negative test results (eg, positive skin test result for ampicillin and negative result for penicillin G), selective oral challenge was performed (eg, oral challenge to penicillin VK).

Statistical Analysis

Data were analyzed from January 9 to 12, 2019. Categorical variables are presented as frequency (percentage) and continuous variables as median (interquartile range [IQR]). All continuous variables were recoded into categorical variables using different cutoff points, and final classification was based on the strength and size of their association with the outcome (positive penicillin allergy test result). Similarly, categorical variables with large numbers of categories were recoded into smaller numbers of categories based on clinical experience and their associations with the outcome.

The primary outcome for the model was any positive result of a penicillin allergy test performed during outpatient or inpatient assessment (SPT, IDT, patch testing, and/or oral challenge [direct or after skin testing]). All predictors considered for the inclusion in the model were obtained from the prospective testing database. Patient predictors included age, sex, ethnicity, history of psychiatric illness, age-adjusted Charlson comorbidity index, and immunocompromised status. Collinearity between age and Charlson comorbidity index was minimal because both variables were recoded in 2 categories. Antibiotic allergy characteristics included number of patient-reported antibiotic allergy labels, time since the

last reported antibiotic allergy (in years), allergy phenotype, and treatment of the index antibiotic allergy episode. Missing values in all variables were coded as a separate category (category unknown).

Univariate analysis was performed using logistic regression to examine the associations between patient/phenotype characteristics outlined above with any penicillin-positive allergy test result. Variables with a prevalence of at least 5% and those with 2-sided $P < .20$ on univariate analysis were included in the multivariable logistic regression model. A backward stepwise procedure was used, eliminating variables with 2-sided $P > .10$ and reincluding variables with 2-sided $P < .05$. This procedure was replicated in 1000 bootstrap samples, and only variables present in at least 60% of replication were included in the final model.¹⁶ Model performance in the original sample was evaluated by calculating the C statistic, Hosmer-Lemeshow statistic, calibration slope, and Brier score.

Internal validation was performed using a regular bootstrap procedure with 500 bootstrapped samples.¹⁷ Bootstrap performance of the final model was evaluated in each bootstrapped sample by calculating the C statistic, and test performance of the same model was evaluated in original sample. The optimism was calculated by subtracting test performance from bootstrap performance. Internally validated performance was calculated by subtracting mean optimism from apparent performance of the final model in the original sample.

A score for the final model was developed by rounding the coefficients of the logit model. Predicted and observed risk were calculated for each score. Sensitivity, specificity, area under the receiver operating characteristic curve (AUC), positive predictive values (PPVs), and negative predictive values (NPVs) were calculated for each cutoff, and the final risk groups were chosen based on NPV and the false-negative rate.

External validation of the model was performed in 3 separate retrospective data sets. Risk score was calculated for each patient, and the model performance was evaluated by comparing AUC, sensitivity, specificity, NPV, and PPV. An additional predictive model was developed using least absolute

Table 2. Baseline Demographics of Penicillin Allergy Cohort From AAT-AMS Database Used in Development and Internal Validation of Clinical Decision Rule

Characteristic (N = 622)	Data ^a
Age, median (IQR), y	60 (48-71)
Female	367 (59.0)
Age-adjusted CCI, median (IQR) ^b	3 (1-5)
Penicillin allergy labels	
Penicillin VK, G, or unspecified	443 (71.2)
Amoxicillin or ampicillin	117 (18.8)
Flucloxacillin or dicloxacillin	29 (4.7)
Combined amoxicillin and clavulanate potassium	33 (5.3)
Allergy phenotypes ^c	
Non-immune mediated (type A)	15 (2.4)
Immediate immune-mediated (type B1)	268 (43.1)
Delayed immune-mediated (type B4)	206 (33.1)
SCAR ^d	5 (0.8)
Rash unspecified	46 (7.4)
Concurrent cephalosporin allergy label	116 (18.6)
Immunocompromised	347 (55.8)
History of mental illness ^e	88 (14.1)
No. of allergy labels, median (IQR)	1 (1-2)
Intradermal test performed	468 (75.2)
Skin prick test performed	498 (80.1)
Patch test performed	8 (1.3)
Oral challenge	
Overall oral challenge performed after skin testing	459 (73.8)
Oral challenge performed after skin testing in the outpatient setting (% of overall)	456 (99.3)
Overall direct oral challenge (no skin testing performed)	167 (26.8)
Direct oral challenge performed in the outpatient setting (% of overall)	26 (15.6)
Any positive allergy test finding ^f	60 (9.6)
Positive penicillin allergy test finding	58 (9.3)

Abbreviations: AAT-AMS, antibiotic allergy testing-antimicrobial stewardship; CCI, Charlson comorbidity index; IQR, interquartile range; SCAR, severe cutaneous adverse reaction.

^a Unless otherwise indicated, data are expressed as number (percentage) of patients.

^b Scores range from 0 to 13, with higher scores indicating a greater number of comorbidities.

^c A indicates non-immune-mediated adverse drug reaction; B1, immediate hypersensitivity; B4, delayed hypersensitivity; unspecified, diffuse pruritic or nonpruritic or localized skin reaction or without any other reported symptoms or signs.

^d Including potential SCAR phenotypes, as per published definitions.¹⁸

^e Includes anxiety, psychosis, or depression.

^f Includes finding positive to alternative β -lactam on testing.

shrinkage and selection operator logistic regression with cross validation (eMethods 3 in the [Supplement](#)). All analyses were performed using Stata, version 15.1 (StataCorp LLC).

Results

Study Population and Setting

The internal derivation and validation cohort included 622 patients (367 female [59.0%] and 255 male [41.0%]; median age, 60 [IQR, 48-71] years); the external validation cohort con-

sisted of 945 patients (662 female [70.1%] and 283 male [29.9%]; median age, 55 [IQR, 38-68] years) (eTable 1 in the [Supplement](#)). During the study period in the internal derivation and validation cohorts, 1219 antibiotic allergies were reported by 773 adult patients who underwent AAT; specifically, 732 penicillin allergies were reported by 679 patients (eFigure 1 in the [Supplement](#)). Fifty-one patients (7.5%) reported multiple penicillin allergies; only 1 entry was used based on a predetermined antibiotic hierarchy (penicillin VK, G, or unspecified, followed by amoxicillin, followed by ampicillin, followed by other). Thirty patients (4.4%) reported an allergy only to an intravenous penicillin without an oral formulation, such as a combination of piperacillin sodium and tazobactam sodium or a combination of ticarcillin disodium and clavulanate; these patients were excluded from the final cohort because intravenous or intramuscular challenges were not performed in the setting of negative test results. In addition, 1 patient was excluded because of missing results of allergy testing. From the remaining 648 patients, 58 had a positive test result (9.0%). Of the 590 with a negative test result, 564 subsequently underwent oral penicillin challenge (95.6%). Only those patients with a negative skin test result followed by an oral challenge (n = 564) and those with a positive skin test result were included (n = 58); a total of 622 adult patients were used for PEN-FAST derivation and internal validation. The baseline characteristics of the study cohort are outlined in [Table 2](#).

Penicillin Allergy Test Positivity

The prevalence of a positive penicillin allergy test was 9.3% (95% CI, 7.2%-11.9%) in the Melbourne cohort. Of those with a positive test result, patients with a positive reaction to SPT, IDT, or oral challenge are outlined in [Table 2](#).

Patient and Phenotypic Factors Associated With a Positive Penicillin Allergy Test

The characteristics associated with a positive penicillin allergy test result in univariate and multivariable analysis are shown in [Table 3](#). The 4 features associated with a positive penicillin allergy test result on multivariable analysis were summarized in the mnemonic PEN-FAST (*penicillin allergy, five or fewer years ago, anaphylaxis/angioedema or severe cutaneous adverse reaction [SCAR], and treatment required for allergy episode*) ([Figure](#)). The major criteria included 5 or fewer years ago (2 points) and anaphylaxis/angioedema or potential SCAR (2 points); the minor criteria (1 point), treatment required for allergy episode. The model showed good discrimination (AUC = 0.808; Hosmer-Lemeshow $\chi^2 = 1.84$; $P = .61$) and calibration (calibration slope, 1; Brier score, 0.07; product-moment correlation between observed and predicted probability, 0.39). Internal validation showed minimal mean optimism of 0.003 with internally validated AUC of 0.805 (eFigure 2 in the [Supplement](#)).

The following 4 risk groups were developed: very low risk (0 points), with a risk of allergy of 0.6%; low risk (1 or 2 points), with a risk of 5%; moderate risk (3 points), with a risk of 20%; and high risk (4 or 5 points), with 50% probability of having a positive penicillin test result (eTable 2 in the [Supplement](#)). A cutoff of less than 3 points for PEN-FAST was chosen that clas-

Table 3. Univariate and Multivariable Analysis of Features Associated With a Positive Penicillin Allergy Test Result in Derivation and Validation Cohort

Clinical characteristic	No. (%) of participants		Univariate analysis		Multivariable analysis ^a				Presence in 1000 bootstrap replications, % ^a	Point score
	Overall (N = 622)	Any penicillin test positive (n = 58)	OR (95% CI)	P value	OR (95% CI)	β Coefficient (95% CI)	P value			
Age, ≥80 y	50 (8.0)	1 (1.7)	0.18 (0.02-1.36)	.10	NA	NA	NA	0	NA	
Age-adjusted CCI ≥1	522 (83.9)	45 (77.6)	0.63 (0.33-1.22)	.17	NA	NA	NA	18.2	NA	
Male	255 (41.0)	25 (43.1)	1.10 (0.64-1.90)	.73	NA	NA	NA	NA	NA	
Nonwhite race	29 (4.7)	3 (5.2)	1.13 (0.33-3.85)	.85	NA	NA	NA	NA	NA	
Any history of psychiatric disease	88 (14.1)	7 (12.1)	0.82 (0.36-1.87)	.63	NA	NA	NA	NA	NA	
Immunocompromised	347 (55.8)	38 (65.5)	1.57 (0.89-2.76)	.12	NA	NA	NA	21.9	NA	
≥2 Allergy labels	182 (29.3)	24 (41.4)	1.81 (1.04-3.16)	.04	NA	NA	NA	27.3	NA	
Anaphylaxis ^{b,c}	25 (4.0)	8 (13.8)	5.15 (2.12-12.52)	<.001	NA	NA	NA	NA	NA	
Angioedema ^b	30 (4.8)	8 (13.8)	3.94 (1.67-9.31)	.002	NA	NA	NA	NA	NA	
Urticaria	137 (22.0)	15 (25.9)	1.26 (0.68-2.35)	.46	NA	NA	NA	NA	NA	
Collapse unspecified (ie, syncope)	18 (2.9)	0	NA	NA	NA	NA	NA	NA	NA	
Diffuse itchy rash	180 (28.9)	19 (32.8)	1.22 (0.68-2.17)	.50	NA	NA	NA	NA	NA	
Diffuse nonitchy rash	86 (13.8)	5 (8.6)	0.55 (0.22-1.43)	.22	NA	NA	NA	NA	NA	
Itch unspecified	8 (1.3)	0	NA	NA	NA	NA	NA	NA	NA	
Localized rash not other ^d	25 (4.0)	1 (1.7)	0.41 (0.05-3.11)	.39	NA	NA	NA	NA	NA	
Rash with skin ulceration	4 (0.6)	0	NA	NA	NA	NA	NA	NA	NA	
Respiratory distress	28 (4.5)	4 (6.9)	1.67 (0.56-4.98)	.36	NA	NA	NA	NA	NA	
Unspecified swelling ^e	52 (8.4)	3 (5.2)	0.57 (0.17-1.90)	.36	NA	NA	NA	NA	NA	
Unknown	54 (8.7)	3 (5.2)	0.55 (0.17-1.82)	.33	NA	NA	NA	NA	NA	
Rash with no other symptoms	241 (38.7)	14 (24.1)	0.47 (0.25-0.88)	.02	NA	NA	NA	0.6	NA	
Severe reaction ^f	377 (60.6)	44 (75.9)	2.20 (1.18-4.10)	.01	NA	NA	NA	16.1	NA	
Rash more than 10 y ago ^g	169 (27.2)	3 (5.2)	0.13 (0.04-0.42)	.001	NA	NA	NA	NA	NA	
Unknown reaction more than 10 y ago ^g	42 (6.8)	1 (1.7)	0.22 (0.03-1.66)	.14	NA	NA	NA	NA	NA	
Anaphylaxis, angioedema, SJS, TENS, DRESS, or AGEPS ^h	60 (9.6)	20 (34.5)	6.89 (3.67-12.94)	<.001	4.74 (2.41-9.33)	1.56 (0.88-2.23)	<.001	95.8	2	
Nonsevere reaction in childhood	190 (30.5)	8 (13.8)	0.34 (0.16-0.73)	.006	NA	NA	NA	24.8	NA	
Treatment required	411 (66.1)	50 (86.2)	3.57 (1.66-7.68)	.001	2.78 (1.24-6.22)	1.02 (0.22-1.83)	.01	74.3	1	
Hospitalization required	214 (34.4)	35 (60.3)	3.25 (1.86-5.66)	<.001	NA	NA	NA	28.8	NA	
ICU admission required ^e	57 (9.2)	9 (15.5)	2.02 (0.93-4.37)	.07	NA	NA	NA	NA	NA	
Previous allergy to the same drug	610 (98.1)	56 (96.6)	0.51 (0.11-2.36)	.39	NA	NA	NA	NA	NA	
Allergy in childhood ^e	193 (31.0)	8 (13.8)	0.33 (0.15-0.71)	.005	NA	NA	NA	NA	NA	
<5 y since last allergy or unknown	175 (28.1)	40 (69.0)	7.06 (3.92-12.73)	<.001	5.96 (3.24-10.96)	1.79 (1.18-2.39)	<.001	100	2	

Abbreviations: AGEF, acute generalized exanthematous pustulosis; CCI, Charlson comorbidity index; DRESS, drug reaction with eosinophilia and systemic symptoms; ICU, intensive care unit; NA, not applicable; OR, odds ratio; SJS, Stevens-Johnson syndrome; TENS, toxic epidermal necrolysis.

^a NA indicates variables not considered for multivariable model owing to $P > .20$ on univariate analysis or prevalence of less than 5%.

^b Not considered in multivariable model owing to prevalence of less than 5% and collinearity with other variables.

^c Adjusted by the clinician if the history was consistent with a cutaneous manifestation plus respiratory, cardiovascular, or gastrointestinal symptoms or acute-onset hypotension or bronchospasm/airway obstruction alone. If the patient was unable to recall the history but was told the phenotype was anaphylaxis, this was used

as the default phenotype.

^d Indicates a rash localized to a single region of the body without other symptoms or signs of hypersensitivity.

^e Indicates generalized or local body swelling, not including angioedema.

^f Included any 1 of acute interstitial nephritis, AGEF, DRESS, TENS, SJS, fixed drug eruption, blistering or ulcerating skin reaction, hematological disorder, severe liver or renal impairment, neurological sequelae, anaphylaxis, angioedema, generalized swelling, urticaria, or respiratory compromise.

^g SJS and TEN also included potentially compatible syndromes of skin reaction with mucosal ulceration.

Figure. PEN-FAST Penicillin Allergy Clinical Decision Rule

PEN	Penicillin allergy reported by patient	<input type="checkbox"/> If yes, proceed with assessment
F	Five years or less since reaction ^a	<input type="checkbox"/> 2 points
A	Anaphylaxis or angioedema	<input type="checkbox"/> 2 points
S	Severe cutaneous adverse reaction ^b	
T	Treatment required for reaction ^a	<input type="checkbox"/> 1 point
		<input type="checkbox"/> Total points
Interpretation		
Points		
<input type="checkbox"/> 0	Very low risk of positive penicillin allergy test <1% (<1 in 100 patients reporting penicillin allergy)	
<input type="checkbox"/> 1-2	Low risk of positive penicillin allergy test 5% (1 in 20 patients)	
<input type="checkbox"/> 3	Moderate risk of positive penicillin allergy test 20% (1 in 5 patients)	
<input type="checkbox"/> 4-5	High risk of positive penicillin allergy test 50% (1 in 2 patients)	

The PEN-FAST clinical decision rule for patients reporting a penicillin allergy uses 3 clinical criteria of time from penicillin allergy episode, phenotype, and treatment required. A total score is calculated using PEN-FAST score in the upper panel, and interpretation for risk strategy is provided in the lower panel.

^a Includes unknown.

^b Forms of severe delayed reactions include potential Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. Patients with a severe delayed rash with mucosal involvement should be considered to have a severe cutaneous adverse reaction. Acute interstitial nephritis, drug induced liver injury, serum sickness and isolated drug fever were excluded phenotypes from the derivation and validation cohorts.

Table 4. Validation of PEN-FAST in Predicting a Positive Penicillin Allergy Test Result in All Derivation and Validation Cohorts

Cohort	No. of patients	No. (%) with positive finding ^a	Validation ^b				
			AUC (95% CI)	Sensitivity (95% CI), %	Specificity (95% CI), %	PPV (95% CI), %	NPV (95% CI), %
Melbourne, Australia	622	58 (9.3)	0.75 (0.68-0.81)	70.7 (57.3-81.9)	78.5 (74.9-81.9)	25.3 (18.8-32.7)	96.3 (94.1-97.8)
Perth, Australia	334	48 (14.4)	0.73 (0.66-0.81)	87.5 (74.8-95.3)	39.9 (34.1-45.8)	19.6 (14.5-25.6)	95.0 (89.4-98.1)
Sydney, Australia	80	27 (33.8)	0.78 (0.68-0.88)	70.4 (49.8-86.2)	84.9 (72.4-93.3)	70.4 (49.8-86.2)	84.9 (72.4-93.3)
Nashville, Tennessee	531	19 (3.6)	0.74 (0.62-0.86)	73.7 (4.8-90.9)	59.8 (55.4-64.0)	6.4 (3.5-10.4)	98.4 (96.3-99.5)

Abbreviations: AUC, area under the receiver operating characteristics curve; NPV, negative predictive value; PPV, positive predictive value.

^b Based on a PEN-FAST score of at least 3.

^a Indicates any penicillin allergy test with a positive finding.

sified 460 of 622 patients (74.0% of the cohort) as at low risk of allergy, of whom only 17 (3.7%) had positive test results for 1 or more penicillin allergy test (2 of 17 for SPT; 13 of 17 for IDT; and 6 of 17 for oral challenge). Of the remaining 162 patients who were classified as at higher risk, 41 (25.3%) had a positive allergy test result. The sensitivity to identify penicillin allergy using this cutoff was 70.7% (95% CI, 57.3%-81.9%); specificity, 78.5% (95% CI, 74.9%-81.9%); PPV, 25.3% (95% CI, 18.8%-32.7%); and NPV, 96.3% (95% CI, 94.1%-97.8%) (Table 4 and eTable 3 in the Supplement).

Validation of PEN-FAST

Results for validation in the 945 adult patients from 3 centers (Sydney, Perth, and Nashville) are demonstrated in Table 4. Overall, the AUC analysis indicated good discrimination for the PEN-FAST scores in all external databases, including 0.81 (95% CI, 0.75-0.86) for Melbourne, 0.81 (95% CI, 0.71-0.91) for Syd-

ney, 0.73 (95% CI, 0.66-0.80) for Perth, and 0.85 (95% CI, 0.74-0.96) for Nashville (eFigure 2 in the Supplement). There was no clear evidence for a lack of fit, indicating good prediction by PEN-FAST of positive penicillin allergy test results (eFigure 3 in the Supplement).

Discussion

PEN-FAST is a clinical decision rule that, in this study, demonstrated the high NPV required for a rule-out test, similar to that elicited from formal penicillin allergy skin-testing studies.^{19,20} A PEN-FAST score of less than 3 was able to exclude severe penicillin allergy. This finding is important because penicillin allergy is increasingly recognized as a public health issue for communities and hospitals,² with well-described deleterious effects on patients and health

economics.^{1,21} With more than 20 million persons in North America likely to be harboring a penicillin allergy label and a global deficit in the number of allergists with drug allergy training,^{10,22} addressing penicillin allergy is becoming the domain of nonallergists.⁷ A barrier to widespread implementation of penicillin allergy assessment is the absence of externally validated point-of-care tools to risk stratify penicillin allergies, in particular the identification of low-risk (nonsevere) penicillin allergies amenable to oral challenge rather than penicillin skin testing.^{23,24} PEN-FAST uses information obtained from patient history to accurately risk stratify patients. This risk stratification can be performed across a spectrum of NPVs appropriate for the care setting and clinician experience, with a PEN-FAST score of 0 equating to an NPV of 99.4% (95% CI, 96.6%-100%) or a PEN-FAST score of less than 3 equating to an NPV of 96.3% (95% CI, 94.1%-97.8%).

Clinical decision rules have been explored to predict true penicillin hypersensitivity. Stevenson et al²⁵ studied 447 Australian patients to identify a low-risk criterion consisting of a benign rash more than 1 year previous (sensitivity, 80.6%; specificity, 60.8%). Their study is a large step forward in further characterizing a low-risk criterion but, as suggested by the authors, is limited by a lack of international validation and heterogeneity of testing in the retrospective cohort. Chiriac et al²⁶ explored a β -lactam clinical decision rule, with derivation performed in a large retrospective data set from France and external validation in smaller prospective data sets (AUC, 0.67; NPV, 83%). The authors found that anaphylaxis and time from event (eg, childhood) were strong predictors, similar to our cohort, but findings were limited by the collective use of all β -lactam allergies, retrospective data collection, and small validation cohorts. Siew et al²⁷ used a retrospective cohort from the United Kingdom (n = 1092) to identify predictors of true allergy and generated a low-risk criteria (NPV of 98.4%) consisting of (1) no anaphylaxis, (2) reaction more than 1 year ago, and (3) no recall of index drug. The editorial praised the simplicity but noted the absence of a wider array of allergy histories (eg, angioedema/swelling), absence of external validation, and applicability to only IgE-mediated allergies.²⁷ Interestingly, Ramsey et al²⁸ recently demonstrated in a randomized clinical trial a low-risk penicillin allergy clinical criterion, with only a 3.8% false-negative rate (cutaneous only or unknown reaction >1 year ago for ages 15-17 years or >10 years ago for age \geq 18 years); all adults in this cohort would have demonstrated a PEN-FAST score of less than 3.²⁹

Limitations

There are limitations to the PEN-FAST rule, such as the exclusion of nonpenicillin β -lactam allergies and some intravenous penicillins (which could not be confirmed with oral challenge), a limited number of patients with SCAR-like phenotypes, predominance of inpatient testing, and applicability to adult patients only. Although external validation was performed in a large cohort (n = 945), missing data included lack of documentation regarding treatment of the acute allergy episode (Nashville and Perth cohorts). The validation in ethnically diverse populations (eg, European, Asian, and African) where the prevalence of penicillin allergy and phenotypes is likely to vary is an important next step. The NPV and AUC of PEN-FAST remained clinically relevant in all tested patient cohorts in this study, despite variations in the prevalence of positive test results at the different study sites. Despite variations in skin testing reagents, similar testing protocols were used in Melbourne, Perth, and Nashville, and oral challenge was the definitive outcome in all cohorts. Patients with SCAR were included, despite no robust criterion standard for testing being available,³⁰ because we believe this reinforces among clinicians the need to identify and be alert to these life-threatening phenotypes that may require avoidance of all penicillins and cephalosporins. The terms used in PEN-FAST (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms) should be recognizable by the target users of this decision rule: allergists, immunologists, infectious disease physicians, internal medicine clinicians, and pharmacists.^{2,20} Further, assessment tools are now available to aid clinicians in appropriate allergy assessments,^{20,31} and such tools could be paired with PEN-FAST. Due to the inherent error rate in the electronic health record, we would advise that PEN-FAST be applied only on a detailed clinical history obtained directly from the patient rather than electronic health record data only.

Conclusions

The current status quo of outpatient penicillin allergy assessments performed by allergists is inadequate to meet current and future demand for AAT,^{10,32} and point-of-care tools are urgently needed to effectively reduce the high burden of patients falsely labeled as penicillin allergic. PEN-FAST potentially allows clinicians to evaluate penicillin allergy risk and severity, thereby encouraging the safe use of β -lactams and oral challenge programs in those patients considered to be at low risk of penicillin allergy.

ARTICLE INFORMATION

Accepted for Publication: February 1, 2020.

Published Online: March 16, 2020.

doi:10.1001/jamainternmed.2020.0403

Author Affiliations: Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Australia (Trubiano, Chua, Holmes); Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia (Trubiano); Peter MacCallum Cancer Centre, Department of Infectious Diseases and The

National Centre for Infections in Cancer, Parkville, Australia (Trubiano, Douglas); Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Australia (Vogrin); Department of Allergy and Immunology, Fiona Stanley Hospital, Murdoch, Australia (Bourke); Faculty of Medicine and Health, University of Sydney, Sydney, Australia (Yun, Groenendijk); Department of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennessee (Stone, Yu, Phillips); Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia (Phillips).

Author Contributions: Drs Trubiano and Vogrin had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Trubiano, Stone, Phillips.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Trubiano, Stone, Groenendijk, Phillips.

Critical revision of the manuscript for important intellectual content: Trubiano, Vogrin, Chua, Bourke, Yun, Douglas, Stone, Yu, Holmes, Phillips.

Statistical analysis: Trubiano, Vogrin, Stone.
Obtained funding: Trubiano.

Administrative, technical, or material support: Trubiano, Chua, Yun, Douglas, Stone, Groenendijk, Phillips.

Supervision: Trubiano, Stone, Phillips.

Conflict of Interest Disclosures: Dr Stone reported receiving grant 1K12HSO26395-01 from the Agency for Healthcare Research and Quality (AHRQ) during the conduct of the study. Dr Phillips reported receiving grants from the National Institutes of Health (NIH) and National Health and Medical Research Council (NHMRC) and personal fees from UpToDate, Inc and BioCryst Pharmaceuticals, Inc outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by a grant from the Austin Medical Research Foundation (AMRF); postgraduate scholarship GNT 1139902 from the NHMRC (Dr Trubiano); a postgraduate scholarship from the National Centre for Infections in Cancer (Dr Trubiano); grants IP50GM115305-01, R21AI139021, R34AI136815, and 1R01HG01086301 from the NIH (Dr Phillips); the NHMRC (Dr Phillips); and grant 1K12HSO26395-01 from the AHRQ (Dr Stone).

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: The departments of Infectious Diseases at Austin Health and Peter MacCallum Cancer Centre assisted with the antibiotic allergy testing services, for which they were not compensated.

REFERENCES

- Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavina MA, Thursky KA; National Antimicrobial Prescribing Survey (NAPS). Antimicrobial allergy "labels" drive inappropriate antimicrobial prescribing: lessons for stewardship. *J Antimicrob Chemother*. 2016;71(6):1715-1722. doi:10.1093/jac/dkw008
- Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. *Lancet*. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9
- MacFadden DR, LaDelfa A, Leen J, et al. Impact of reported beta-lactam allergy on inpatient outcomes: a multicenter prospective cohort study. *Clin Infect Dis*. 2016;63(7):904-910. doi:10.1093/cid/ciw462
- Trubiano JA, Leung VK, Chu MY, Worth LJ, Slavina MA, Thursky KA. The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients. *Antimicrob Resist Infect Control*. 2015;4:23. doi:10.1186/s13756-015-0063-6
- Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: a cohort study. *J Allergy Clin Immunol*. 2014;133(3):790-796. doi:10.1016/j.jaci.2013.09.021
- Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. *Clin Infect Dis*. 2017;65(1):166-174. doi:10.1093/cid/cix244
- Trubiano J, Phillips E. Antimicrobial stewardship's new weapon? a review of antibiotic allergy and pathways to "de-labeling". *Curr Opin Infect Dis*. 2013;26(6):526-537. doi:10.1097/QCO.000000000000006
- Bourke J, Pavlos R, James I, Phillips E. Improving the effectiveness of penicillin allergy de-labeling. *J Allergy Clin Immunol Pract*. 2015;3(3):365-34.e1. doi:10.1016/j.jaip.2014.11.002
- Marwood J, Aguirrebarrena G, Kerr S, Welch SA, Rimmer J. De-labelling self-reported penicillin allergy within the emergency department through the use of skin tests and oral drug provocation testing. *Emerg Med Australas*. 2017;29(5):509-515. doi:10.1111/1742-6723.12774
- Trubiano JA, Beekmann SE, Worth LJ, et al. Improving antimicrobial stewardship by antibiotic allergy delabeling: evaluation of knowledge, attitude, and practices throughout the emerging infections network. *Open Forum Infect Dis*. 2016;3(3):ofw153. doi:10.1093/ofid/ofw153
- Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD). *Ann Intern Med*. 2015;162(10):735-736. doi:10.7326/L15-5093-2
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8
- Trubiano JA, Douglas AP, Goh M, Slavina MA, Phillips EJ. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. *J Allergy Clin Immunol Pract*. 2019;7(4):1341-1343.e1. doi:10.1016/j.jaip.2018.09.014
- Rawlins MDTJ. *Textbook of Adverse Drug Reactions*. Oxford University Press; 1977.
- Pichler WJ. Drug sensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ, ed. *Drug Hypersensitivity*. S Karger Pub; 2007:168-189. doi:10.1159/000104199
- Austin PC, Tu JV. Bootstrap methods for developing predictive models. *Am Stat*. 2004;58(2):7. doi:10.1198/0003130043277
- Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. *J Clin Epidemiol*. 2001;54(8):774-781. doi:10.1016/S0895-4356(01)00341-9
- Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. *Lancet*. 2017;390(10106):1996-2011. doi:10.1016/S0140-6736(16)30378-6
- Solensky R, Jacobs J, Lester M, et al. Penicillin allergy evaluation: a prospective, multicenter, open-label evaluation of a comprehensive penicillin skin test kit. *J Allergy Clin Immunol Pract*. 2019;7(6):1876-1885.e3. doi:10.1016/j.jaip.2019.02.040
- Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. *JAMA*. 2019;321(2):188-199. doi:10.1001/jama.2018.19283
- Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of methicillin resistant *Staphylococcus aureus* and *Clostridium difficile* in patients with a documented penicillin allergy: population based matched cohort study. *BMJ*. 2018;361:k2400. doi:10.1136/bmj.k2400
- Derrick MI, Williams KB, Shade LMP, Phillips EJ. A survey of drug allergy training opportunities in the United States. *J Allergy Clin Immunol Pract*. 2018;6(1):302-304. doi:10.1016/j.jaip.2017.08.003
- Banks TA, Tucker M, Macy E. Evaluating penicillin allergies without skin testing. *Curr Allergy Asthma Rep*. 2019;19(5):27. doi:10.1007/s11882-019-0854-6
- Trubiano JA, Smibert O, Douglas A, et al. The safety and efficacy of an oral penicillin challenge program in cancer patients: a multicenter pilot study. *Open Forum Infect Dis*. 2018;5(12):ofy306. doi:10.1093/ofid/ofy306
- Stevenson B, Trevenen M, Klinken E, et al. Multicenter Australian study to determine criteria for low- and high-risk penicillin testing in outpatients. *J Allergy Clin Immunol Pract*. 2020;8(2):681-689.e3.
- Chiriac AM, Wang Y, Schrijvers R, et al. Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database. *J Allergy Clin Immunol Pract*. 2018;6(1):139-148.e2. doi:10.1016/j.jaip.2017.04.045
- Siew LQC, Li PH, Watts TJ, et al. Identifying low-risk beta-lactam allergy patients in a UK tertiary centre. *J Allergy Clin Immunol Pract*. 2019;7(7):2173-2181.e1. doi:10.1016/j.jaip.2019.03.015
- Ramsey A, Caubet JC, Blumenthal K. Risk stratification and prediction in beta-lactam allergic patients. *J Allergy Clin Immunol Pract*. 2019;7(7):2182-2184. doi:10.1016/j.jaip.2019.05.045
- Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized, controlled trial. *J Allergy Clin Immunol Pract*. 2019;7(7):2163-2170. doi:10.1016/j.jaip.2019.05.037
- Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. *J Allergy Clin Immunol*. 2019;143(1):66-73. doi:10.1016/j.jaci.2018.10.030
- Devchand M, Urbancic KF, Khumra S, et al. Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. *J Allergy Clin Immunol Pract*. 2019;7(3):1063-1065.e5. doi:10.1016/j.jaip.2018.07.048
- Trubiano JA, Worth LJ, Urbancic K, et al; Australasian Society for Infectious Diseases Clinical Research Network; Australasian Society of Clinical Immunology and Allergy. Return to sender: the need to re-address patient antibiotic allergy labels in Australia and New Zealand. *Intern Med J*. 2016;46(11):1311-1317. doi:10.1111/imj.13221